The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)

Clin Infect Dis. 2022 Apr 9;74(7):1268-1270. doi: 10.1093/cid/ciab648.


Previous studies have shown that certain vaccines induce suboptimal responses in people living with human immunodeficiency virus (HIV, PLWH). However, responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.

Keywords: COVID; PLWH; SARS-CoV-2; mRNA vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • HIV
  • HIV Infections*
  • Humans
  • Immunity, Cellular
  • Immunity, Humoral
  • SARS-CoV-2
  • Vaccines, Synthetic
  • mRNA Vaccines


  • Antibodies, Viral
  • Vaccines, Synthetic
  • mRNA Vaccine
  • mRNA Vaccines
  • BNT162 Vaccine